FDA approves Trazimera (trastuzumab-qyyp), biosimilar to Herceptin

FDA today approved Trazimera (trastuzumab-qyyp), a biosimilar to U.S.-licensed Herceptin (trastuzumab).

A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA approved biological product, known as a reference product. The biosimilar also must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.